PathAI to Present at Digestive Disease Week

BOSTON, April 30, 2025 (GLOBE NEWSWIRE) — PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of IBD ExploreTM and AIM-HI UCTM at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA.1 IBD Explore is an AI-powered tool providing comprehensive and quantitative characterization of the inflammatory IBD microenvironment. AIM-HI UC™ is the only AI-powered Geboes scoring tool that assists pathologists in accurately and reproducibly measuring Geboes subgrades for histological stage and improvement to enable ulcerative colitis research and clinical trials.

PathAI has recently launched updated versions of these tools on the AISight Translational Research platform1. IBD Explore v2.0 includes classification of additional cell types and tissue regions that were not included in prior versions, including macrophages, fibroblasts, and lymphoid aggregates. AIM-HI UC v2.0 now integrates PathAI’s pathology universal transformer (PLUTO) foundation model and shows highly accurate performance, as highlighted in poster Su1904 at DDW.

Poster Details

Title: Consortium-driven Development of Pathology Foundation Model-based Approaches for Automated Scoring of Histopathology in Ulcerative Colitis (Abstract Number Su1904)

  • Session: IBD: Disease Activity Assessment and Monitoring
  • Date and Time: Sunday, May 4, 2025, from 12:30 – 1:30 p.m. PT
  • Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI

Title: Quantitative Histologic Features of the Inflammatory Microenvironment using Digital Pathology Prior to Adalimumab Treatment Associate with Response in Patients with Ulcerative Colitis (Abstract Number Tu2044)

  • Session: Emerging Tools and Technologies and In Vivo Models of GI Diseases
  • Date and Time: Tuesday, May 6, 2025, from 12:30 – 1:30 p.m. PT
  • Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI

Follow PathAI on LinkedIn for more updates from DDW 2025.

About PathAI

PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.

Footnote

1AIM-HI UCTM, IBD ExploreTM, and AISight are For Research Use Only. Not for use in diagnostic procedures.

Company Contact
Elizabeth Storti
elizabeth.storti@pathai.com

Media Contact
Daniel Donato
LifeSci Communications
ddonato@lifescicomms.com

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

53 minutes ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

53 minutes ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

53 minutes ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

53 minutes ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

54 minutes ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

4 hours ago